Alfred Penfold

PM Group
Technical Director - GMP / Regulatory Compliance
Alfred Penfold has more than 35 years of experience in the pharmaceutical and biotechnology industry working for GSK, Catalent, Pfizer and PM Group. At Pfizer, he held multiple positions, including Engineering Lead for all manufacturing operations in the US and Canada. Alf has held similar roles in Latin America, Europe, and Asia. He was later responsible for all serialization deployments within Pfizer and has advised the FDA on serialization. Alf now works for PM Group as their Technical Director for GMP / Regulatory Compliance and has performed GMP design reviews, quality risk assessments and prepared agency review meetings, such as FDA Type C meetings, for clients in Europe, the US, and Asia. He is a member of the ISPE Regulatory Quality Harmonisation Committee’s EMEA Regional Focus Group’s steering committee, a member of the ISPE Europe Leadership Team and an elected member of the PHSS Management Committee. Alf has been an ISPE member since 1999.

Related Articles

Sterile Manufacturing banner image
iSpeak Blog
Data Management Requirements for Sterile Manufacturing

Ronald Bauer, PhD and Christina Meissner, PhD from the Austrian Agency for Health and Food Safety (AGES) provided a much-anticipated presentation on the requirements for data management in light of the revised Annex 1 at the 2024 ISPE Pharma 4.0™ and Annex 1 Conference in Rome, Italy in December 2024.

Requirements for data management- regulatory
iSpeak Blog
Data Management Requirements for Sterile Manufacturing

Ronald Bauer, PhD and Christina Meissner, PhD from the Austrian Agency for Health and Food Safety (AGES) provided a much-anticipated presentation on the requirements for data management in light of the revised Annex 1 at the 2024 ISPE Pharma 4.0™ and Annex 1 Conference in Rome, Italy in December 2024.

Training-APQ-v2.png
iSpeak Blog
Biotech Sessions at the 2025 ISPE Europe Annual Conference Highlight ATMPs including Large Molecules and Cell and Gene Therapies

The biotech sector, which includes advanced therapy medicinal products (ATMPs) including large molecules and cell and gene therapies, has been the fastest growing market in the pharmaceutical industry for years and this is not expected to change in the next few decades. In addition to products already on the market and new products in development, the market will additionally grow in...

Regulatory Panel Discussions: Annex 1 Implementation from the Regulators’ Point of View
iSpeak Blog
Regulatory Panel Discussions: Annex 1 Implementation from the Regulators’ Point of View

The updated EU GMP Annex 1 Revision: Manufacture of Sterile Medicinal Products released in August 2022 introduced changes which require more stringent sterile manufacturing processes, including implementing a contamination control strategy and new technology to reduce the risk of contamination. Regulators discussed those changes and how they impact manufacturing practices during panel...